A New Approach page top left image

Funding Opportunity Announcement

NCDDN Fellowship in Drug Discovery

The Laboratory for Drug Discovery in Neurodegeneration (LDDN) is a program of the Harvard NeuroDiscovery Center and has a mission to identify chemical agents that can be used as lead structures for the development of therapeutics for Neurodegenerative Diseases.  To discover these compounds, the LDDN screens their large collection of drug-like molecules for the ability of these compounds to modulate the biological activity of molecular and cellular processes that are thought to play causative roles in neurodegenerative diseases.  Optimization of these compounds is achieved by focused programs of medicinal chemistry.  To facilitate these activities, the LDDN has a permanent staff of a dozen scientists with industrial experience in assay design, high-throughput screening, informatics, and medicinal chemistry.

The LDDN was awarded a grant from the NINDS Cooperative Program in Translational Research that has allowed us to establish a Fellowship Program in Drug Discovery Research.  The goal of this program is to establish a collaborative relationship between PIs and the LDDN via the sponsorship of a postdoctoral fellow (in some cases graduate students) from your lab, to do work in our biotech-like atmosphere where we can assist in the transformation of your basic neurobiological findings into drug discovery programs.  We offer your postdoc a fully-funded year at our facility, plus our expertise in assay optimization and medicinal chemistry.  Promising projects will be continued as a collaboration to further optimize the chemical compounds identified.

Funding is available for five projects and will cover salary, supplies, and a housing allowance for the fellows to reside in the Boston area for a period of one year.  The proposed drug discovery project should be based on on-going studies of the applicant and mentor, and have clear relevance for neurodegenerative disease.  If you are interested, please explore the LDDN section of our website where you will find further details about the program.

Applications are due Monday, March 30, 2009  (March 2, 2009 for Letter of Intent). 

Decisions will be announced May 2009, for a start date of September 8, 2009. 

General enquires can be sent to:
        Ross L. Stein, PhD
        Director, Laboratory for Drug Discovery in Neurodegeneration
        phone:  617-768-8651
        email:  This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
.